VentriFlo, Inc.

VentriFlo, Inc. is a medical technology company focused on developing innovative blood pumping systems that emulate the natural functionalities of the human heart to enhance patient care. Founded in 2019, VentriFlo, Inc. operates from Pelham, US, and specializes in the design of advanced cardiopulmonary support systems.

The company has completed one funding round, receiving USD 10. 00 mn in Series A funding on August 15, 2019, led by individual investors. VentriFlo Inc. specializes in the development of the VentriFlo True Pulse Pump, a pioneering blood pumping system designed to deliver pulsatile blood flow that mimics the natural function of the human heart.

This innovative technology aims to enhance patient outcomes, reduce healthcare costs, and improve safety for both pediatric and adult patients requiring cardiopulmonary support during surgical procedures or in intensive care units. The True Pulse Pump functions through a unique mechanism that provides complete stroke volume, natural cadence, and physiological rest, thus addressing the limitations of traditional continuous flow systems. The device is currently in the research and development phase and is designated for research use only, with no sales made to end users at this stage. VentriFlo's primary market focus includes healthcare institutions such as hospitals and surgical centers in the United States and select regions in Europe, where advanced medical technologies are integral to patient care.

VentriFlo Inc. is currently in the development phase of its flagship product, the VentriFlo True Pulse Pump, which is not yet available for commercial sale. As such, the company does not generate revenue through direct sales or conventional business transactions at this time. Revenue generation strategies may evolve to include partnerships with healthcare facilities, distribution agreements with medical device wholesalers, or direct-to-consumer models once the product becomes ready for market.

The pricing structure for the True Pulse Pump and its associated consumables will likely be established based on the device's clinical benefits and competitive positioning within the medical device market. Overall, the company's revenue landscape will depend on future commercial launches and the establishment of a customer base in both domestic and international healthcare markets. VentriFlo, Inc. plans to utilize the USD 10.

00 mn raised in its Series A funding to advance the development of the True Pulse Pump, targeting a launch date to be determined based on research outcomes. Additionally, the company aims to enter new markets, particularly expanding its reach across healthcare institutions in Europe by 2023. The funding will support product development, marketing efforts, and establishing distribution channels necessary for successful market entry.